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valuing beneﬁts concerned with avoiding amputation
twice less than physicians. Anyway the price of
prostagladin E1 is about 350 USD for a period of treat-
ment that is much less than the median sum of money
named by both groups of respondents.
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Hypothermia resulting from invasive surgical procedures
can increase blood and ﬂuid loss and complicate the 
post-operative course of recovery. Therefore, hypother-
mia can be quite costly to treat. The Arctic SunTM Model
100 is new a non-invasive perioperative warming device,
which controls body temperature through single use
Arctic Sun Energy Transfer PadsTM regulated by a control
module.
OBJECTIVE: To compare the initial surgical and inten-
sive care unit (ICU) outcomes and costs resulting from
use of the Arctic Sun vs. standard care of temperature
management in patients undergoing off-pump coronary
artery bypass (OPCAB) surgery. 
METHODS: Data from two clinical studies conducted at
a major university were combined with other published
data to compare surgical outcomes and treatment costs
to the hospital associated with patient re-warming
methods.
RESULTS: Preliminary ﬁndings in OPCAB procedures
indicate post-operative hypothermia incidence is lower
for patients using the Arctic SunTM Model 100 (5% n =
58) compared to patients warmed using the standard
warming methods (48%, n = 48). An additional cost of
over $338.00 per patient for blood products and ﬂuids
received by patients was incurred for the standard care
population compared to the Arctic SunTM population.
Compared to normothermic patients, patients who are
hypothermic have an average increased hospital stay of
5.8 days ($2,616.96), and an average increased ICU time
of 4.2 hours ($236.88). Combining these costs with the
costs to treat infections, morbid cardiac events, and addi-
tional lab work, the total additional costs for complica-
tions due to hypothermia can easily exceed $8,270 per
patient. 
CONCLUSION: The Arctic SunTM is an effective tem-
perature management device for OPCAB patients. Com-
bining the Arctic SunTM clinical data with published
economic data suggests that the Arctic SunTM for tem-
perature management in OPCAB procedures could save
over $33,800 in blood product costs and over $355,000
in complication costs per 100 patients.
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OBJECTIVE: Patients on long-term anticoagulation
requiring interruption of therapy for a surgical procedure
historically have been hospitalized to receive “bridging
therapy” with continuous infusion intravenous unfrac-
tionated heparin (UFH). Recently, low-molecular weight
heparins such as enoxaparin have been reported to have
comparable safety and efﬁcacy in this indication, and can
be administered on an outpatient basis. The objective of
this study was to compare the costs of bridging therapy
with enoxaparin versus UFH in this patient population. 
METHODS: We conducted a cost-minimization analysis
of bridging therapy from the perspective of a third-party
health insurer. Patient treatment protocols were set forth
to reﬂect current clinical practice. Bridging therapy was
assumed to take place over an eight-day period, reﬂect-
ing three preoperative days, one day of surgery, and four
postoperative days. Three alternative bridging strategies
were considered: (1) UFH 30,000 units/day administered
in hospital; (2) enoxaparin 1.0mg/kg self-administered
twice-daily by the patient at home; and (3) enoxaparin
1.5mg/kg administered once-daily in the patient’s home
by a visiting nurse. Various secondary sources were 
used to estimate the costs of drug acquisition, ancillary
supplies, provider services, and hospitalization. Analyses
were performed for day surgery, surgery requiring
overnight stay, and surgery requiring a stay of 4+ days.
RESULTS: Bridging therapy with UFH in hospital costs
$4,397 per patient for day surgery, $3,818 for procedures
requiring an overnight stay, and $2,080 for procedures
requiring a stay of 4+ days (2001 US$). Corresponding
cost estimates for patient-administered enoxaparin are
$663, $673, and $743. Cost estimates for nurse-
administered enoxaparin are $990, $935, and $771,
respectively.
CONCLUSIONS: Bridging therapy with enoxaparin 
at home whether patient-administered or nurse-
administered is substantially less costly than bridging
with UFH in hospital. The magnitude of cost savings is
highest for day surgery and lowest for surgeries requiring
a prolonged recovery in hospital.
PCV29
INFLUENCE OF COMORBID CONDITIONS IN
THE HOSPITALIZATION OF ANGINA PATIENTS
Morris L, Henderson SC, von Allmen H, Gale B, Margolis J
IMS Health, Plymouth Meeting, PA, USA
173Abstracts
OBJECTIVE: To determine if certain diagnoses and
comorbidities inﬂuence the risk of hospitalization for
angina patients. 
METHODS: Study was conducted using IMS HEALTH’s
LifeLinkTM database, a U.S. employer claims database 
consisting of more than 1.8 million covered lives, with
linked medical and pharmacy claims for employees, depen-
dents, and retirees from 1991 forward. Patients were diag-
nosed with angina in the period March 1, 1999 to
February 29, 2000. Unstable angina patients were placed
in a single cohort. Stable angina patients were further clas-
siﬁed based on the presence of hypertension, congestive
heart failure (CHF), diabetes, or other heart disease in the
36 months preceding their angina diagnosis.
RESULTS: 125,453 patients met the inclusion criteria—
32,672 with unstable angina and 92,781 with stable
angina. Patients with unstable angina were signiﬁcantly
more likely to be hospitalized (53.3%) than patients 
with stable angina (27.3%) (p < 0.001). When compar-
ing unstable to stable angina patients with comorbid con-
ditions, patients with unstable angina were more likely 
to be hospitalized than stable angina patients, regardless
of the combination of comorbidities in stable angina
patients (odds ratios between 1.20 and 10.47). Stable
angina patients with comorbid hypertension, diabetes,
and CHF had the most similar risk of hospitalization
compared to unstable angina patients, but still were sig-
niﬁcantly less likely to be hospitalized (OR = 0.83, 95%
CI = 0.79, 0.87). Unstable angina patients had the highest
likelihood of hospitalization compared to patients with
stable angina and no comorbidities (OR = 10.47, 95% CI
= 9.76, 11.22). Among stable angina patients, hospital-
ization rates were highest for patients with comorbid
CHF (ranging from 36.6% for patients with CHF only 
to 48.7% for patients with CHF, hypertension, and 
diabetes).
CONCLUSIONS: Patients with unstable angina were 
signiﬁcantly more likely than stable angina patients to 
be hospitalized, even if the stable angina patients had a
number of complicating comorbid conditions. Presence 
of unstable angina greatly increased the risk of 
hospitalization.
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The National Institutes of Health’s Adult Treatment Panel
III (ATP-III) guidelines deﬁne the population of hyperc-
holesterolemic patients for whom drug therapy is sug-
gested. A wide body of evidence indicates that elevated
low-density lipoprotein (LDL-C) is a major risk factor for
coronary heart disease (CHD). Thus, the ATP-III guide-
lines target LDL-C levels for reduction in hypercholes-
terolemic patients in an effort to reduce CHD risk. The
drug of choice is an HMG-CoA Reductase Inhibitor
(statin), which has demonstrated effectiveness in reducing
LDL-C.
OBJECTIVES: To determine if the relative cost-
effectiveness of the three most commonly prescribed
statins is affected by the initial LDL-C and ATP-III goals. 
METHODS: A Monte Carlo simulation was used to
model therapeutic course to target using data from pub-
lished trials including (pre-treatment LDL-C distribu-
tions, expected LDL-C reduction by drug and dose and
ATP-III LDL-C goals). Data from this model were entered
into a cost-effectiveness analysis model in Data 4.0
(TreeAge Software, Inc, 2001). One-way sensitivity 
analyses were conducted upon pre-treatment LDL-C 
distribution, statin performance, and costs of: drugs, 
time away from work/home, ofﬁce visits, laboratory tests
and mono-therapy failure.
RESULTS: Atorvastatin dominated the model, having 
the lowest drug cost and failure rate, regardless of initial
LDL-C level or ATP-III guideline goal. Base case (mean
LDL-C 188.9mg/dl [SD 24.0] and goal LDL-C of 
100mg/dl) cost-effectiveness ratios for atorvastatin, sim-
vastatin and pravastatin were $(US) 1,721, $(US) 3,641
and $(US) 22,029 respectively. Alternative case (mean
LDL-C 149.6mg/dl [SD 16.8] and goal LDL-C of 100
mg/dl) cost-effectiveness ratios for atorvastatin, simvas-
tatin and pravastatin were $(US) 965, $(US) 1,552 and
$(US) 2,498 respectively.
CONCLUSIONS: Atorvastatin was the most cost-
effective treatment among the tested statins. Cost-
effectiveness rankings were insensitive to all tested vari-
ables. Cost-effectiveness was primarily determined by the
performance characteristics of each drug and drug cost.
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It is well known that surgery performed under general
anesthesia commonly results in hypothermia. Surgical
hypothermia is a serious, but preventable, condition. 
It is becoming increasingly important, however, to
provide decision-makers with evidence of the cost-
effectiveness as well as the clinical beneﬁt of preventive
measures.
OBJECTIVE: Using the hospital perspective, the out-
comes and cost-effectiveness of the Arctic Sun Model 
100 for the prevention of hypothermia in patients under-
going off-pump coronary artery bypass surgery is
explored. 
